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A synthetic biochemistry platform for cell free
production of monoterpenes from glucose
Tyler P. Korman1, Paul H. Opgenorth1 & James U. Bowie1
Cell-free systems designed to perform complex chemical conversions of biomass to biofuels
or commodity chemicals are emerging as promising alternatives to the metabolic engineering
of living cells. Here we design a system comprises 27 enzymes for the conversion of glucose
into monoterpenes that generates both NAD(P)H and ATP in a modified glucose breakdown
module and utilizes both cofactors for building terpenes. Different monoterpenes are
produced in our system by changing the terpene synthase enzyme. The system is stable for
the production of limonene, pinene and sabinene, and can operate continuously for at least
5 days from a single addition of glucose. We obtain conversion yields 495% and titres
415 g l 1. The titres are an order of magnitude over cellular toxicity limits and thus difficult
to achieve using cell-based systems. Overall, these results highlight the potential of synthetic
biochemistry approaches for producing bio-based chemicals.
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T
erpenes comprise one of the largest classes of industrially
relevant bioactive natural products and have found wide
use as flavours, fragrances, biofuels, commodity chemicals,
vitamins and pharmaceuticals1–5. While many of the industrial
and pharmaceutically relevant terpenes in use are plant-derived6,
low yields from natural sources limit their use and makes
production subject to the unpredictability of agricultural boom
and bust cycles7,8. Production in metabolically engineered
microbes could therefore provide an attractive alternative for
increased terpenoid production9–12. Escherichia coli and
Saccharomyces cerevisiae have both been successfully engineered
to produce monoterpenes such as limonene13, pinene14 and
sabinene15; sesquiterpenes such as santalene16,17, bisabolene18
and amorphadiene19; and diterpenes such as sclareol20,
taxadiene21 and carotinoids22. Nevertheless, the high titres and
yields needed for economic viability of high-volume chemical
uses have generally not been realized. Even in the case of
monoterpenes limonene and pinene where established supply
streams exist, their wider adoption as bio-safe solvents and
biofuels is limited by amounts produced in nature23. Titres of
terpenes are typically very low (o0.5 g l 1), and in even the best
reported cases are only around r1.5 g l 1 (refs 24,25). The
notable exception is amorphadiene, which can be produced at
40 g l 1 in S. cerevisiae, but the yields are too low (17% carbon
yield) to be useful for low-cost chemicals such as biofuels19.
Multiple factors limit the success of engineered microbes for
terpene production (and biochemical production in general),
including toxicity of products or intermediates, competing
endogenous pathways, difficult pathway optimization (at both
the transcriptional and translational level) and expensive product
isolation from complex growth media26. In the case of
monoterpenes limonene and pinene, a cellular toxicity limit of
r0.5% (5 g l 1) is a major contributor to low titres and presents
a key barrier for production in a microbial host27,28.
Cell-free production provides an alternative approach to
chemical transformations that can ease the technical challenges of
engineering microorganisms and the limitations imposed by
requiring cell viability26. Rather than engineer cells to produce
and house the desired biochemical pathway, the cell-free approach
simply mixes enzymes together in a reaction vessel (either from
crude preparations or purified)29–32. While freedom from the
constraints of the cell has many advantages, it also poses challenges
because the complex regulatory systems and biochemical
replenishing systems that exist in cells are eliminated. The design
of enzyme systems that can be self-sustaining for long periods of
time requires special considerations—a process we call synthetic
biochemistry32.
Here we use synthetic biochemistry to build a system for the
production of monoterpenes from glucose. The system is stable
and functions continuously for at least 5 days without any further
additions of cofactors or enzymes. The high yields and titres for
limonene (12.5±0.3 g l 1) and pinene (14.9±0.6 g l 1) are
nearly an order of magnitude higher than that has been
demonstrated in living systems. Our results suggest that
commodity chemicals and pharmaceutical intermediates derived
from acetyl-CoA and ATP are accessible through synthetic
biochemistry systems.
Results
Overview of in vitro monoterpene biosynthesis from glucose.
The challenges facing synthetic biochemistry can be seen in the
conversion of glucose to monoterpenes by a combination of the
Embden–Meyerhof–Parnas (EMP) glycolytic and the mevalonate
pathways. The mevalonate pathway requires 3 acetyl-CoA,
2 NADPH and 3 ATP to yield the terpene-building blocks
isopentenyl pyrophosphate or dimethylallyl pyrophosphate. From
1.5 glucose, standard EMP glycolysis (hereafter referred to as
‘glycolysis’) will yield the 3 acetyl-CoA and the net 3 ATP needed,
but will also produce 6 NADH, creating two problems: (1) an
excess of reducing equivalents is produced; and (2) they are of the
wrong type (NADH rather than NADPH) so that NADþ would
not be recycled. We have previously developed a method to
handle NAD(P)H/NAD(P)þ balancing by creating enzymatic
purge valve nodes32,33 that use a combination of NADþ - and
NADPþ -utilizing dehydrogenases and NADH oxidase (NoxE) so
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Figure 1 | Schematic of the synthetic biochemistry system for conversion of glucose to monoterpenes. Enzymes in each submodule (coloured boxes)
are labelled as described in the text and Supplementary Table 1. ATP-consuming and -generating steps are shown in purple and blue, respectively. The
NADPH-generating purge valve is shown in red while the NADPH-consuming top of the mevalonate pathway is shown in orange. Solid arrows show the
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that NADPH can be generated via the NADPþ -utilizing
dehydrogenase, but excess reducing equivalents can be purged
via NoxE to maintain carbon flux (see ref. 31 for description). The
ATP pay-in phase of glycolysis presents an additional
complication because if ATP is used too rapidly in the first
hexokinase (Hex) step, there will be no ATP left to allow flux
through the phosphofructokinase step34. Finally, high-energy
phosphate for all metabolites (for example, the g-phosphate of
ATP) is ultimately (re)generated from inorganic phosphate (Pi),
so that Pi concentrations can affect flux through the system.
The goal of this study was to show that glucose breakdown
through glycolysis can produce enough carbon building
blocks and ATP to drive an important anabolic process
(for example, the mevalonate pathway). So far, complex cell-free
systems for building chemicals have either avoided the use
of ATP completely30 or stoichiometrically balance ATP use
and consumption during catabolic reactions only35. While
ATP-specific regeneration systems have been developed, these
are generally simple systems consisting of only a few enzymes
that utilize sacrificial substrates (for example, polyphosphate
or acetyl-phosphate)36,37. It remains unclear whether excess ATP
(for example, the net 2 ATP produced from glycolysis) can be
effectively used outside the cell to drive anabolic pathways in a
fully recyclable manner30,31. In the synthetic biochemistry system
we designed (Fig. 1 and Supplementary Fig. 1), ATP, NADPH
and acetyl-CoA are generated using glycolysis reconstituted from
purified components (Supplementary Table 1). NADPH
production is regulated with a new molecular purge valve at the
glyceraldehyde-3-phosphate dehydrogenase (Gap) step (rather
than the pyruvate dehydrogenase (Pdh) step described
previously32) by including a mutant Gap (mGap) that is
specific for NADPþ along with NoxE. Geranyl-pyrophosphate
is ultimately produced through the canonical mevalonate
pathway using the acetyl-CoA, ATP and NADPH output from
the engineered EMP pathway. Various monoterpenes can then be
made simply by adding different monoterpene synthases in the
final step following geranyl-pyrophosphate production.
Importantly, pyrophosphate released by the prenyltransferase
and terpene synthase steps is then converted back to Pi by
the action of a pyrophosphatase, ensuring that all cofactors
(ATP/ADP/NAD/NADP/CoA/Pi) are recycled continuously
in situ and there is no build-up of any metabolite besides the
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Figure 2 | Modelling and optimization of enzyme levels for conversion of glucose to limonene. (a) Levels for glucose (black line), limonene (blue line)
and cofactors (ATP, ADP, G6P, F16BP, Pi and PPi) in an optimized CoPASI model starting at 500mM glucose and a time of 20,000 s (5.6 h). Glucose and
limonene levels are plotted on the left axis and cofactor levels are plotted on the right axis. (b) Parameter scan in CoPASI showing the dependence of
limonene production on units of Hex varied between 0.05 and 0.15 units. (c) Parameter scan in CoPASI showing the dependence of limonene production
on units of Pdh varied between 1 and 50 units. (d) Parameter scan in CoPASI showing the dependence of limonene production on starting Pi varied
between 1 and 50mM. (e) Experimental data showing the dependence of limonene production on units of Hex, Pdh and Pi. (f) Experimental data showing
the dependence of limonene production on the ratio of Hex and Pfk units to the kinases in the mevalonate pathway: Mvk; Pmvk; and Mdc (MevKs).
The reactions in c and d were started with the addition of 250mM glucose and analysed after 16 h.
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intended product. We also added catalase, glutathione and
glutathione reductase to ensure the system maintains a reduced
environment (Supplementary Table 1).
Modelling with CoPASI to identify potential bottlenecks. To
ensure that our designed system could run effectively in theory,
and to determine factors that may contribute to maximizing
overall titres of limonene from glucose, we developed a computer
model using CoPASI38. Although we have not measured kinetic
parameters for the enzymes used experimentally, our goal was to
explore fundamental features of the overall system design.
We therefore used kinetic parameters defined for homologous
enzymes where needed to obtain a reasonable model. Equations
describing enzyme kinetics for glycolysis and the mevalonate
pathway were taken from established models describing
yeast metabolism39 (Supplementary Note) with values for Km,
Vmax and Keq based on published values in the BRENDA
database40 and previous modelling experiments39. The Gap purge
valve (including EcGap, mGap and NoxE) and pyrophosphatase
were also included in the model. The final parameters and
equations are provided in the Supplementary Note.
A virtual time course was performed starting with 500mM
glucose and system parameters (for example, Vmax or starting
cofactor concentration) were adjusted to identify features
important for the reaction to go to completion (final values
shown in Supplementary Table 2). We focused on parameters
that would allow the reaction to go to completion rather than
improve reaction rate because we wanted to develop a system that
was robust and sustainable, that is, could run for long periods of
time without intervention (Fig. 2a). Modelling with CoPASI
suggests that system sustainability is particularly sensitive to Hex
(Fig. 2b) and Pdh enzyme activity (Fig. 2c), and also to initial
Pi concentration (Fig. 2d).
The importance of Hex and Pi is perhaps unsurprising as Hex
and Pi are instrumental in ATP usage and recycling. It has been
noted previously that too much Hex activity leads to a build-up of
glucose-6-phosphate (G6P) and depletion of ATP, which is
needed for the phosphofructokinase reaction34. ATP depletion
can thereby block passage through the ATP pay in phase
of glycolysis. Similarly, sequestration of Pi in hexose phosphates
(for example, G6P and fructose-1,6-bisphosphate) can block the
Gap step, shutting down glycolysis (Supplementary Fig. 2a).
The strong dependence of the reaction sustainability on Pdh
activity is less clear. Since Pdh is followed by the first three
ATP-independent steps of the mevalonate pathway (Fig. 1 and
Supplementary Fig. 1), it is possible that too little Pdh causes a lag
before ATP usage via Mvk, Pmvk and Mdc. As a result of this lag,
Hex and Pfk might out-compete the kinases in the mevalonate
pathway and again phosphate would become sequestered in
hexose phosphates at the top of glycolysis. Overall, CoPASI
modelling suggests that initial levels of Hex, Pi and Pdh are the
most critical contributors to successful conversion of glucose to
limonene (Supplementary Fig. 2b).
Implementation of in vitro monoterpene production system.
Since the modelling results suggest that the system design could
function in a sustainable fashion, we set out to implement the
pathway. We set initial cofactor concentrations and the relative
glycolysis enzyme levels as described in a prior work41. The rest of
the enzymes levels were set so they would not be rate-limiting.
We then varied Hex, Pdh or Pi concentrations over a 10-fold
range, keeping the rest of the system concentrations constant.
Figure 2e shows the dependence of limonene titres on the amount
of Hex, Pi or Pdh input during a 16 h reaction. For Pi or Pdh,
the extent of reaction increases with increasing loading until
a threshold is met, consistent with the COPASI modelling results.
The limonene titre increased with increasing units of Hex activity
to a certain point after which the limonene titre began to decline.
If too much Hex was added, the rate of glucose phosphorylation
outpaced Pfk and Mvk, Pmvk and Mdc activity. As shown in
Fig. 2f, adding additional units of Pfk, Mvk, Pmvk and Mdc
recovers limonene titre to starting conditions. The results suggest
that if the kinase steps are not balanced, Pi becomes sequestered
in G6P, fructose-6-phosphate and fructose-1,6-bisphosphate
(FBP; hexose phosphates), and Gap activity ceases. Clearly, care
must be taken to balance Hex activity with all other kinases.
Purge valve requirement for sustainable limonene production.
To test whether a molecular purge valve is necessary to drive
the mevalonate pathway using glycolysis, we developed a
new molecular purge valve at the Gap step (composed of an
NADþ -dependent Gap from E. coli, an NADPþ -dependent
mGap from Geobacillus stearothermophilus and NoxE)
and evaluated the consequences of eliminating purge valve
components. As shown in Fig. 3, leaving out any part of the new
molecular purge valve significantly compromises the ability of the
system to convert glucose into limonene. In fact, leaving out
NoxE completely abolished limonene production from glucose as
seen in prior characterization of other purge valves32,33. The
dependence on NoxE is not surprising since both the molecular
purge valve and Pdh rely on NoxE activity for unimpeded flux.
With the full system, 2.57±0.15 g l 1 (average of three
independent measurements; n¼ 3) limonene could be produced
in 24 h. Therefore, the new molecular purge valve at Gap can
produce NADPH and maintain enough flux to provide ATP and
acetyl-CoA for limonene production.
Continuous production of limonene from glucose. To test
efficient and sustainable in vitro production of limonene from
glucose, we set up a semi-optimized system (Supplementary
Table 3) and allowed the reaction to proceed for multiple days
from a single addition of glucose. To monitor function and
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longevity, a single addition of 100mM (Fig. 4a), or 200mM
glucose (Fig. 4b) was added at the start and the reaction was
evaluated at various time-points for limonene production,
remaining glucose and levels of ATP and Pi (Fig. 4). Within 2
days, 4.94±0.18 g l 1 (n¼ 3) limonene was produced
from 100mM glucose (Fig. 4a), which corresponds to a 100%
theoretical yield at a maximum productivity of B0.1 g l 1 h 1.
Monitoring glucose (total hexose and hexose phosphates), ATP
and Pi show that all glucose input is consumed and ATP and Pi
cycle accordingly (Fig. 4c). When twice as much glucose was
input (200mM), glucose consumption and limonene production
rates were nearly constant over 5 days reaching 8.87±0.59 g l 1
(n¼ 3) limonene and correspond to a theoretical yield of 97.6%
(Fig. 4b). When ATP and Pi were monitored concurrently
(Fig. 4d), both ATP and Pi levels decrease to a low basal level
(B200 mM and 2mM for ATP and Pi, respectively) and then
fluctuate over the course of 4 days as would be expected (that is,
when ATP is higher, Pi is lower and vice versa). When 200mM
glucose was input, the limonene titre did not plateau until day 4
when all of the available glucose had been consumed, suggesting
the system could progress further. Finally, to determine the full
extent of biosynthetic capability for the in vitro system, 500mM
glucose was input and limonene production monitored over 7
days. At day 7, limonene reached a final titre of 12.5±0.3 g l 1
(n¼ 3; Fig. 5) with a total yield of 88.3%±4.6% (n¼ 3) of
theoretical suggesting little or no loss of carbon due to side
reactions. Our in vitro production of 12.5 g l 1 limonene directly
from glucose is nearly an order of magnitude higher than has
so far been demonstrated for limonene production in living
systems42 and 42 times the toxicity limit of between 0.02 and
0.5% for E. coli or S. cerevisiae27,43.
Production of other monoterpenes from glucose. To test
whether our synthetic biochemistry system could be used as
a broad platform for the production of other monoterpenes, we
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attempted to produce pinene and sabinene from glucose. To
make pinene or sabinene, the appropriate monoterpene synthase
was simply swapped with the limonene synthase used above. For
pinene synthesis, a-pinene synthase from Picea sitchensis was
used, which has been shown to produce a mixture of 77%
a-pinene and 22% b-pinene44. For sabinene production the
limonene synthase mutant N345A was used, which produces
sabinene as its major product along with smaller amounts of
other monoterpenes45. Starting with 500mM glucose,
monoterpene production was allowed to proceed for 7 days
and then quantified by GC (Supplementary Fig. 3). Pinene titre
(sum of a-pinene and b-pinene nearly identical to distribution
in ref. 44) reached 14.9±0.6 g l 1 (n¼ 3) while sabinene
titre (total monoterpenes, similar distribution to ref. 45) was
15.9±0.4 g l 1 (n¼ 3) with yields of 103.9%±8.1% (n¼ 3) and
94.5%±4.7% (n¼ 3) of theoretical, respectively (Fig. 5). Like
limonene production, these values are at least an order of
magnitude higher than microbial production for pinene14
and sabinene15 and multiple times higher than the toxicity limit
for these compounds15,43.
Discussion
Our results show that industrially relevant complex biomolecules
such as monoterpenes can be produced in vitro directly from
glucose using a synthetic biochemistry platform. Specifically, we
find that the ATP and the carbon-building block acetyl-CoA
generated by glycolysis can be used to drive the biosynthesis
of complex compounds directly from glucose, a low-cost,
renewable feedstock. This represents a significant expansion of
synthetic biochemistry platform as both acetyl-CoA and ATP are
needed for the biosynthesis of many desirable products besides
terpenes. We were able to produce monoterpenes at high titres
(12.5±0.3, 14.9±0.6 and 15.9±0.4 g l 1 for limonene, pinene
and sabinene, respectively) and yields (88.3±4.6%, 103.9±8.1%
and 94.5±4.7% of theoretical, respectively), and production was
continuous over many days without any further additions of
enzyme or cofactors. While the flux reported here is still about an
order of magnitude below rates needed for industrial production
(0.1 versus 1–2 g l 1 h 1), this work significantly improves on a
previous, less-complicated system41 from phosphoenolpyruvate
(PEP) to isoprene in both rate (0.014 g l 1 h 1) and overall
extent of reaction (for example, titre and scale). Rates for in vitro
production of less-complex molecules such as ethanol34,46, 2,3-
butanediol47, mevalonate31 and polhydroxybutyrate33 from
glucose in either a lysate or purified system range from 0.7 to
as high as 47.9 g l 1 h 1, suggesting that the rate for in vitro
terpene production could be raised if either more terpene
synthase were used or the rate was significantly improved
through engineering. Therefore, with further optimization of
reaction conditions as well as in vitro evolution of enzyme
stability and activity (for example, terpene synthase), it should be
possible to develop a faster system that functions for much
longer.
Without the limitations of toxicity and substrate competition,
it should also be possible to expand the synthetic biochemistry
platform to make sesquiterpenes and diterpenes simply by
changing two proteins. Because the system works with an excess
of NADPH, it is also possible to envision the incorporation of
modifying enzymes such as cytochrome P450s to further expand
the number and diversity of products generated.
Our results suggest that synthetic biochemistry has the
potential to reach industrially relevant production parameters
for a wide range of complex molecules that are difficult to
produce in vivo. The key will be to keep enzyme costs low by
finding stable enzymes so they can be used for long periods of
time, methods for recycling the enzymes and inexpensive
purification methods. Implementing a more stable system with
engineered enzymes that last for weeks or months will
significantly lower the cost of the enzymes not only in terms of
dollars but also in initial input of glucose needed to produce
enzymes (which was not taken into consideration for our yield
calculations). The longer the proteins last (that is, higher total
turnover number), the larger the reduction in up-front costs,
including glucose. Our monoterpene platform demonstrates that
in vitro systems can reach yields and titres required for industrial
production of specialty bio-based chemicals but significant
improvements are necessary in areas such as stability and
total turnover number before synthetic biochemistry can begin
to challenge synthetic biology for production of commodity
chemicals from biomass.
Methods
Chemicals and reagents. All buffers, reagents and cofactors (for example, bis-tris
propane, glucose, limonene, pinene, sabinene, FBP, ATP, NAD(P)þ , coenzyme A
and so on) were purchased from Sigma-Aldrich. Yeast Hex (H6380) was from
Sigma. Hexanes, isopropyl myristate and nonane were from ARCOS and were the
highest grade available. Liquid and solid media for growth of E. coli was from
Fisher Scientific (BD Difco).
Cloning and purification of enzymes. All enzymes were cloned into pET28a(þ )
(Novagen) with an N-terminal 6xHis-tag unless otherwise noted (Supplementary
Table 1). NCBI gene accession codes used in this work are listed in Supplementary
Table 1. Primers used for cloning are listed in Supplementary Table 4. E. coli strain
BL21Gold(DE3) (Agilent) was used for both cloning and overexpression of
His-tagged proteins. Genes were amplified from plasmid or genomic DNA using
HotStart Taq Mastermix (Denville) and then cloned into PCR-amplified vectors
using a modified Gibson method as described previously41,48. Mutagenesis of
limonene synthase to introduce the N345A mutation45 and GsGap to construct the
D32A/L33R/T34K triple mutant was done using the Quickchange Site-Directed
Mutagenesis Kit (Stratagene).
For overexpression and purification of all constructs (except Pdh, see below),
1 l of Luria broth (LB) media containing antibiotic was induced with 0.4mM
isopropyl-b-D-thiogalactoside once the optical density 600 nm reached 0.6. After
16 h incubation, soluble 6xHis-tagged proteins were purified from clarified cell
lysates by Ni-NTA affinity chromatography, adjusted to 10% glycerol, flash-frozen
with liquid N2 and stored at  80 C until use. For terpene synthases, enzymes
were concentrated to B20mgml 1 with a 30 kDa molecular weight cut-off
concentrator (Amicon) before freezing.
Assembly and purification of Pdh complex. All three subunits of the Pdh
complex (AceE, AceF and Lpd) were cloned as N-terminal 6xHis-tag constructs as
above. The AceE and Lpd subunits of Pdh were expressed and purified individually
by Ni-NTA. For AceF overexpression, the media was supplemented with 0.2mM
(±) lipoic acid before induction with isopropyl-b-D-thiogalactoside. Following
lysis, AceF was precipitated by two additions of ammonium sulfate to 25 and 55%.
The pellet from the 55% ammonium sulfate addition was dialysed into 25mM
Tris-Cl (pH 8.5), and purified by ion-exchange chromatography using a 25ml
HiTrap Q column. Fractions containing AceF were pooled, and AceF was
isolated by ultracentrifugation (105,000 g for 3 h). The pellet containing AceF was
resuspended in 25mM Tris-Cl (pH 8) containing 10% glycerol and then mixed
with Ni-NTA-purified AceE and Lpd. The mixture was allowed to incubate
at 4 C for 30min to form the complex and then isolated by ultracentrifugation
(105,000 g for 3 h). The resulting yellow pellet was resuspended in 7ml 25mM
Tris-Cl (pH 8) and 0.1M NaCl containing 50% glycerol, and stored at  20 C.
CoPASI modelling. CoPASI v4.16 was downloaded from http://copasi.org/
(ref. 38). For simulation and analysis of the combined glycolytic and mevalonate
pathways designed in this study, Km and kcat values were obtained from the
BRENDA database40 (Supplementary Table 2) and rate equations (Supplementary
Note and Supplementary equations (1)–(23)) were derived based on descriptions of
yeast metabolism39. A time course task was run with a timescale of 20,000 s and
parameters adjusted until a steady rate of conversion of glucose into limonene was
obtained. Next, a parameter scan task was performed for the Vmax of various
enzymes or starting concentration of various cofactors (for example, Pi or ATP)
over either a 10- or 50-fold range in 20 steps to identify bottlenecks and optimum
starting conditions. Bottleneck enzymes (for example, Pdh) were identified by
starting with a 250- to 500-fold excess over Hex and systematically decreasing
each enzyme to a 5- to 10-fold excess followed by monitoring limonene production
over 20,000 s. Pdh was the only enzyme that failed to run to completion during
the given time frame.
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Enzyme assays. Enzymes used in this work were assayed as described
previously32,33,41. In general, enzymes that produce or consume NAD(P)H were
monitored at 340 nm. Enzymes that do not produce or consume NAD(P)H directly
were coupled to an enzyme that does (for example, FBP aldolase coupled to
glyceraldehyde-3-phosphate dehydrogenase). Enzymes that consume or produce
ATP were monitored at 340 nm using a coupled assay to NADH consumption
through the activity of pyruvate kinase and lactate dehydrogenase. All readings
were performed in triplicate (n¼ 3) using a SpectraMax M5 Plate Reader.
Initial limonene production from glucose. Initial reactions for the continuous
in vitro bioconversion of glucose to limonene were composed of 100mM Tris-Cl
(pH 7.5), 6mM MgCl, 10mM KCl, 2mM ADP, 2mM ATP, 1mM FBP, 1.5mM
CoA, 0.5mM NADþ , 1.5mM NADPþ , 100mM glucose, 0.5mM thiamine pyr-
ophosphate, 0.25mM 2,3 bisphosphoglycerate, 5mM reduced glutathione and
10mM Pi in a final volume of 200 ml. Glutathione reductase and catalase were
simply added as a precaution to prevent oxidation over the course of 7 days. We
did not optimize or investigate the need for these components. As the overall
system design with the purge valve produces an excess of NADPH, there is suf-
ficient NADPH in the system to supply glutathione reductase. The enzyme con-
centrations are given in Supplementary Table 3. The reactions were initiated with
the addition of glucose followed by carefully overlaying the reaction sample with
600ml isopropyl myristate. The reactions were allowed to proceed for at least 24 h
and gentle shaking with limonene production monitored by gas chromatography
equipped with a flame ionization detector (GC-FID).
Initial levels of glycolysis enzyme loadings were set based on data from Scopes
and Welch34 for in vitro ethanol production from glucose. Levels for Pdh and
mevalonate pathway enzymes were set based on measured (PhaA, Hmgs, Hmgr,
Mvk, Pmvk and Mdc) or reported (Idi and Fpps) units per milligram values such
that none of the mevalonate pathway enzymes (with the exception of limonene
synthase) were limiting. Minimal optimization was performed by varying key
enzyme (Hex, Pdh, NoxE, Gap and mGap) and cofactor (NADþ , ATP and
phosphate) levels until a maximum titre could be established in 24 h that was
dependent on the terpene synthase activity. Final enzyme loadings are listed in
Supplementary Table 3.
Continuous terpene production from glucose. Reactions were set up in triplicate
at a volume of 200ml in 2ml glass vials and incubated uncapped with an organic
overlay at 25 C and gentle shaking. Each reaction contained 100mM bis-tris
propane (pH 7.5), 20mM potassium phosphate (pH 7.5), 1mM FBP, 4mM ATP,
1.5mM NADPþ , 0.2mM NADþ , 1.5mM CoA, 6mM MgCl2, 10mM KCl,
0.5mM thiamine pyrophosphate, 0.25mM 2,3 bisphosphoglycerate and 5mM
glutathione. For limonene and pinene production, GsFpps mutant S82F was used
in combination with Mentha spicata limonene synthase (produces 100% 4S-
limonene) or P. sitchensis a-pinene synthase (produces 5:1 ratio of a and b pinene),
respectively. For sabinene production, M. spicata limonene synthase mutant
N345A was used (which produces sabinene as its major product along with smaller
amounts of five other monoterpenes). The total catalyst load is detailed in
Supplementary Table 3. Reactions were initiated with the addition of 125, 250 or
500mM (final) glucose and then immediately overlaid with 600 ml isopropyl
myristate. Reactions were allowed to proceed for the time indicated, vortexed for
5 s and centrifuged for 2min at 16,060 g to separate the aqueous and organic
layers. For analysis and quantification of terpene production, 75 ml of the organic
layer was mixed with 175ml hexanes and analysed by GC-FID. For analysis of
residual glucose, ATP and phosphate, the bottom aqueous layer was separated to a
new tube, brought back to 200 ml with buffer and heat-treated for 2min at 95 C to
denature proteins. Samples were then centrifuged (16,060 g for 2min) and stored
at  20 C until analysis.
The yield was calculated by dividing the moles of monoterpene produced by the
theoretical moles of monoterpene that could be produced from the moles of
glucose that entered the system (that is, glucose consumed, not total glucose input).
The amount of glucose that entered the system was calculated by the amount of
glucose measured at t¼ 0 minus the amount of glucose remaining at t¼ 7 days. All
reactions were performed in triplicate (n¼ 3).
Analytical methods. Terpenes isolated in the organic layer were analysed by
GC-FID (HP5890II) equipped with a HP-INNoWax column (0.32mm 30m,
Agilent). A volume of 1 ml was injected and terpenes were identified and quantified
by comparison to an authentic standard curve (limonene, a-pinene or sabinene).
Representative traces are shown in Supplementary Fig. 3. The carrier gas was
helium with a flow rate of 5mlmin 1. The oven temperature was kept at 70 C for
3min, raised to 260 at 5 Cmin 1 and then held at 260 C for 3min. The inlet and
detector temperatures were kept at 250 and 300 C, respectively.
For analysis of glucose, a coupled enzymatic assay was performed based on
reduction of NADþ to NADH by Gap. Briefly, heat-treated samples were diluted
and 2 ml was added to 200ml assay mix containing 100mM Tris-Cl (pH 7.5), 5mM
MgCl2, 10mM KCl, 1mM ATP, 2mM NADþ , 7mM Pi and fresh Hex, Pgi, Pfk,
Ald, Tpi, Gap and Pgk. The change in absorbance was monitored for 10min at
340 nm. The amount of glucose present was calculated based off a standard curve
from known quantities of glucose.
For analysis of ATP, the ATP Bioluminescent Assay Kit (Sigma-Aldrich) was
used. Before performing the quantification, the ATP Assay Mix was diluted
625-fold with ATP-Assay Mix Dilution buffer. To quantify ATP, 100 ml of
a 1:100 diluted sample was added to 100 ml ATP Assay Mix and the luminescence
was measured immediately. A standard curve for ATP was run concurrently
and used to calculate the amount of ATP present.
For analysis of Pi, the Malachite Green Phosphate Detection Kit (R&D Systems)
was used. A volume of 1 ml of a 1:100 dilution of sample was added to 49 ml
H2O and then processed according to the manufacturer’s directions. Phosphate was
calculated by comparison to a standard curve run concurrently with known
amounts of Pi.
Data availability. NCBI gene accession codes used in this work are listed in
Supplementary Table 1. All the other data supporting the findings of this study are
available within the paper and its Supplementary Information files and from the
corresponding author on reasonable request.
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